Overview

A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of nasal PYY3-36 on weight loss post 24 weeks of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Nastech Pharmaceutical Company, Inc.
Treatments:
Sibutramine